ArticleArchives of dermatological research2025
Interleukin-13 in immunohistochemistry: implications for Grover disease, morphea, and immune checkpoint inhibitor-induced bullous pemphigoid.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-13 (IL-13), a key T-helper 2 cytokine, has a central role in type 2 inflammation and is implicated in various skin disorders. This study investigated the IL-13 immunohistochemical expression in skin biopsies from patients with atopic dermatitis (AD), psoriasis vulgaris, morphea, Grover's disease, and immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP). AD biopsies showed the highest IL-13 expression (mean 27.4%), consistent with its established role in the pathogenesis. Psoriasis displayed moderate positivity (mean 8.62%), indicating IL-13's possible involvement in hybrid or phenotypic overlap forms. Minimal expression was detected in Grover's disease (1.8%) and ICI-BP (2.13%), while no positivity was observed in morphea. These findings highlight the diverse roles of IL-13 across skin disorders, with potential implications for targeted therapies.
Indexed as
Identifiers
39951157What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.